123 related articles for article (PubMed ID: 36096678)
1. β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
Hicks AJ; Ponsford JL; Spitz G; Dore V; Krishnadas N; Roberts C; Rowe CC
Neurology; 2022 Sep; 99(11):e1131-e1141. PubMed ID: 36096678
[TBL] [Abstract][Full Text] [Related]
2. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
3. Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale.
Rowe CC; Jones G; Doré V; Pejoska S; Margison L; Mulligan RS; Chan JG; Young K; Villemagne VL
J Nucl Med; 2016 Aug; 57(8):1233-7. PubMed ID: 26912446
[TBL] [Abstract][Full Text] [Related]
4. Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden.
Bourgeat P; Krishnadas N; Doré V; Mulligan R; Tyrrell R; Bozinovski S; Huang K; Fripp J; Villemagne VL; Rowe CC
J Prev Alzheimers Dis; 2023; 10(2):251-258. PubMed ID: 36946452
[TBL] [Abstract][Full Text] [Related]
5. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176
[TBL] [Abstract][Full Text] [Related]
6. Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury.
Mohamed AZ; Cumming P; Srour H; Gunasena T; Uchida A; Haller CN; Nasrallah F;
Neuroimage Clin; 2018; 19():716-726. PubMed ID: 30009128
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
8. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
Winer JR; Maass A; Pressman P; Stiver J; Schonhaut DR; Baker SL; Kramer J; Rabinovici GD; Jagust WJ
JAMA Neurol; 2018 Feb; 75(2):227-235. PubMed ID: 29228071
[TBL] [Abstract][Full Text] [Related]
9. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
Josephs KA; Weigand SD; Whitwell JL
Neurology; 2022 May; 98(22):e2282-e2292. PubMed ID: 35314506
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
11. Mesial temporal tau in amyloid-β-negative cognitively normal older persons.
Krishnadas N; Doré V; Groot C; Lamb F; Bourgeat P; Burnham SC; Huang K; Goh AMY; Masters CL; Villemagne VL; Rowe CC;
Alzheimers Res Ther; 2022 Apr; 14(1):51. PubMed ID: 35395950
[TBL] [Abstract][Full Text] [Related]
12. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
13. Tau Imaging in Late Traumatic Brain Injury: A [
Vanderlinden G; Michiels L; Koole M; Lemmens R; Liessens D; Van Walleghem J; Depreitere B; Vandenbulcke M; Van Laere K
J Neurotrauma; 2024 Feb; 41(3-4):420-429. PubMed ID: 38038357
[TBL] [Abstract][Full Text] [Related]
14. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
15. Baseline [
Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
17. Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.
Köbe T; Gonneaud J; Pichet Binette A; Meyer PF; McSweeney M; Rosa-Neto P; Breitner JCS; Poirier J; Villeneuve S;
JAMA Netw Open; 2020 Feb; 3(2):e1920780. PubMed ID: 32031648
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tau deposition using
Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
[TBL] [Abstract][Full Text] [Related]
19. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [
Tissot C; Servaes S; Lussier FZ; Ferrari-Souza JP; Therriault J; Ferreira PCL; Bezgin G; Bellaver B; Leffa DT; Mathotaarachchi SS; Chamoun M; Stevenson J; Rahmouni N; Kang MS; Pallen V; Margherita-Poltronetti N; Wang YT; Fernandez-Arias J; Benedet AL; Zimmer ER; Soucy JP; Tudorascu DL; Cohen AD; Sharp M; Gauthier S; Massarweh G; Lopresti B; Klunk WE; Baker SL; Villemagne VL; Rosa-Neto P; Pascoal TA
J Nucl Med; 2023 Mar; 64(3):452-459. PubMed ID: 36396455
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
